Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET
01 Febbraio 2024 - 6:15PM
Crossject to host a business briefing on commercial strategy on
February 6 at 17:30 CET
Dijon, France, February 1, 2024
-- 18:15 CET - Crossject (ISIN:
FR0011716265; Euronext: ALCJ), a specialty pharma company
developing needle-free auto-injectors for emergency
situations, will hold a conference call on its commercial
strategy in the U.S. and Europe on February 6, 2024 at 17:30 CET.
The presentation will be held in English.
Patrick Alexandre, Crossject’s CEO and Executive
Chairman, and Olivier Gire, COO of Specialty Pharma, will provide a
business update following the January 4th announcement about
entering into a strategic partnership with Syneos Health, a leading
fully integrated biopharmaceutical solutions organization, to
prepare for the commercial launch of Crossject’s ZEPIZURE®
innovative rescue therapy for epileptic seizures in the U.S.
The leadership will also provide a general business update and
discuss the Company’s progress towards its strategic
objectives.
To register for the webcast, please use the following
details:
https://us06web.zoom.us/webinar/register/WN_NcTN4As6R0i483uALLXFgw
Webcast recording will be available after the event.
About Crossject
Crossject SA (Euronext: ALCJ;
www.crossject.com) is an emerging specialty pharma company based in
France and the U.S. It is in advanced regulatory development for
ZEPIZURE®, anepileptic rescue therapy, for which it was awarded a
$60 million contract with the U.S.Biomedical Advanced Research and
Development Authority (BARDA). ZEPIZURE® is based on the Company’s
award-winning needle-free autoinjector ZENEO®, designed to enable
patients and untrained caregivers to easily and instantly deliver
emergency medication via intramuscularinjection on bare skin or
even through clothing. The Company’s other products in
developmentinclude rescue therapies for allergic shocks, adrenal
insufficiencies, opioid overdose and asthmaattacks.
For further information, please contact:
Investors Natasha DrapeauCohesion Bureau+41 76 823
75 27natasha.drapeau@cohesionbureau.com |
MediaSophie BaumontCohesion Bureau+33 6 27 74 74
49sophie.baumont@cohesionbureau.com |
|
- Crossject_Press release_Webcast_EN
Grafico Azioni Crossject (EU:ALCJ)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Crossject (EU:ALCJ)
Storico
Da Set 2023 a Set 2024